Background & Aims
Previous research in the Madsen Lab have led to the development of a lipidated peptide inhibitor of neuronal synaptic plasticity that alleviates neuropathic pain in preclinical models. Here we applied an innovative labeling technique in combination with tissue clearing and 3D imaging to visualise the tissue distribution of the peptide inhibitor.
Methods
We labeled the peptide inhibitor with the VivoTag flurorescent dye from Revvity and, after subcutanoues administration in naïve and spared nerve injury (SNI) mice, applied tissue clearing and 3D imaging techniques to visualize the VivoTag-peptide distribution in the neural systems.
Results
Following a subcutaneous injection of the VivoTag-peptide, the predominant localization is in peripheral tissues, with undetectable levels in the spinal cord and brain. This observation, in concert with other findings from our lab, suggests that the peptide has a potential impact on peripheral neurons.
Conclusions
These findings are important in the context of existing neuropathic pain treatments, as these primarily target the central nervous system (CNS), often resulting in prominent adverse effects. The peripheral retention of the VivoTag-peptide makes it a promising candidate for relieving neuropathic pain with potentially fewer side effects.
References
NA
Presenting Author
Ida Buur Kanneworff
Poster Authors
Ida Buur Kanneworff
MSc
University of Copenhagen
Lead Author
Sara E. Jager
PhD
University of Copenhagen
Lead Author
Grace A Houser PhD
University of Copenhagen
Lead Author
Kathrine Louise Jensen PhD
University of Copenhagen
Lead Author
Kenneth Lindegaard Madsen PhD
University of Copenhagen
Lead Author
Topics
- Pain Imaging